News – Page 942 – Endpoints News

Portola gets EU clearance to market Andexxa under new name; Four biotechs set terms for Nasdaq debut

7 years ago

FDA tags Bayer's prostate cancer drug for priority review as drugmaker gears up against rivals

7 years ago

Roiled by C-suite turmoil and a CRL, Immunomedics salutes CMO Rob Iannone as he makes a quick exit

7 years ago

After promising M&A and buybacks to revive long-term prospects, Biogen refreshes board with three appointments to ...

7 years ago

Eyeing RNAi potential in cancer and fibrosis, trans-Pacific biotech Sirnaomics lines up $47M Series C

7 years ago

Fired for code of conduct violations, Ian Smith still grabbed a multimillion-dollar stock package at Vertex — but ...

7 years ago

As Praluent Q1 sales miss Wall Street expectations, FDA expands drug's label to reflect CV risk reduction

7 years ago

Three biotechs reveal some secrets about themselves as they gun for $271M-plus in IPOs

7 years ago

Len Schleifer and George Yancopoulos once again land in the top ranks of the highest paid execs in biopharma

7 years ago

Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile

7 years ago

Celgene submits EU marketing pitch for luspatercept; Bausch Health wins FDA approval for topical psoriasis treatment

7 years ago

Keytruda PhIII failure in gastric cancer blights Merck's quest for frontline dominance

7 years ago

Canine club: Elanco Animal Health makes takeover play for partner Aratana in up to $245M deal

7 years ago

‘Something needs to change’: An Allergan analyst spells out why next week’s vote could still spark a major ...

7 years ago

Roche delays $4.3B Spark buyout — again — as FTC review drags on

7 years ago

Celebrating sustained sales growth, AstraZeneca quietly executes some aging mid-stage drug projects

7 years ago

Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO

7 years ago

DoJ expands crackdown on Medicare kickback schemes — Astellas and Amgen to pay nearly $125M to resolve allegations

7 years ago

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up ...

7 years ago

Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise

7 years ago

Top 20 players: Everybody loves an orphan — especially when they come with blockbuster sales and a long run of ...

7 years ago

As it takes Lartruvo off the shelves, Lilly is setting up program to provide drug access to current patients

7 years ago

Martin Shkreli gets a transfer to Brooklyn federal prison in wake of his latest rule-breaking escapades behind bars

7 years ago

Another one of Bristol-Myers' PD-1/CTLA-4 combo studies bites the dust

7 years ago

First page Previous page 939 940 941942943 944 945 Next page Last page